Leap Therapeutics Q1 net loss $41.9M on $29.6M IPR&D charge; cash $102M

CYPHERPUNK TECHNOLOGIES INC.

2023-Q1 EPS reported -$0.32

Net loss $41.9M ($10.4M Q1'22); includes $29.6M IPR&D charge from Flame acquisition.
R&D expense $38.9M, G&A $3.8M; cash $102.0M at Mar 31, 2023.
Completed Part A enrollment in Phase 2 DeFianCe study of DKN-01 in CRC; initial data mid-2023.
Acquired Flame Biosciences, adding anti-Claudin18.2 candidate FL-301 and ~$50M cash.
Will present updated long-term data from DisTinGuish study in GEA at ASCO June 5, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CYPHERPUNK TECHNOLOGIES INC. reported first quarter ended March 31, 2023 results: net income Net Loss was $41.9 million.

Period: first quarter ended March 31, 2023
Net income: Net Loss was $41.9 million
Result: reported results

Exact text from the filing

On May 15, 2023, Leap Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

CYPHERPUNK TECHNOLOGIES INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-060130

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.